Details for New Drug Application (NDA): 017407
✉ Email this page to a colleague
The generic ingredient in CATAPRES is clonidine. There are twenty-two drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the clonidine profile page.
Summary for 017407
Tradename: | CATAPRES |
Applicant: | Boehringer Ingelheim |
Ingredient: | clonidine hydrochloride |
Patents: | 0 |
Profile for product number 001
Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 0.1MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | Yes |
Profile for product number 002
Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 0.2MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | Yes |
Profile for product number 003
Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 0.3MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | Yes |
Expired US Patents for NDA 017407
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Boehringer Ingelheim | CATAPRES | clonidine hydrochloride | TABLET;ORAL | 017407-001 | Approved Prior to Jan 1, 1982 | ⤷ Subscribe | ⤷ Subscribe |
Boehringer Ingelheim | CATAPRES | clonidine hydrochloride | TABLET;ORAL | 017407-003 | Approved Prior to Jan 1, 1982 | ⤷ Subscribe | ⤷ Subscribe |
Boehringer Ingelheim | CATAPRES | clonidine hydrochloride | TABLET;ORAL | 017407-002 | Approved Prior to Jan 1, 1982 | ⤷ Subscribe | ⤷ Subscribe |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription